Obesity is a common disorder in the industrialized world. The major environmental factor associated with the rising prevalence of obesity is an increasingly sedentary lifestyle, compounded by greater levels of caloric intake. Recent studies [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] have shown that in the central nervous system (CNS), neuropeptide Y (NPY) has been implicated in obesity and feeding, anxiety and depression, endocrine function and metabolism.
Obesity is a common disorder in the industrialized world. The major environmental factor associated with the rising prevalence of obesity is an increasingly sedentary lifestyle, compounded by greater levels of caloric intake. Recent studies [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] have shown that in the central nervous system (CNS), neuropeptide Y (NPY) has been implicated in obesity and feeding, anxiety and depression, endocrine function and metabolism. 1) More particularly it was observed that food intake was inhibited by antisense oligodeoxynucleotides to the NPY 5 receptors. 4) Therefore there is a great interest in the synthesis of NPY receptor antagonists acting as antagonists on NPY 5 receptors. Some potent and selective NPY 5 receptor antagonists have been described in the literature [13] [14] [15] [16] [17] [18] and their affinities were assessed through in vitro data over transfected CHO cells. However for most of them no in vivo data were published, 19) this is the case for compound 1 ( Fig. 1 ) which is active in vitro (IC 50 ϭ8.3 nM) but inactive in vivo. We hypothetized that the exchange of the pyrazole ring by a pyridazine ring, in abolishing an intramolecular hydrogen bond between oxygen from amide function and the heterocyclic nitrogen, could lead a better central biodisponibility: in addition, pyridazines are known to have a good central bioavailability. 20) Hereafter we report the synthesis and biological evaluation of a series of pyridazine analogues of compound 1 (Fig. 1) .
To acceed to these compounds, we propose a 3-step synthesis of a series of 3-acetamido-6-arylpyridazines 5a-k.
The first strategy we envisaged for the synthesis of 3-N-(2-naphtylacetamido)-6-phenylpyridazine 5b was based on a the sequence shown in route a (Chart 1): treatment of commercially available 3,6-dichloropyridazine 2 with aqueous ammonia 21) to yield the 3-amino-6-chloropyridazine 3, coupling reaction between 3-amino-6-chloropyridazine 3 and 2-naphtylacetic acid in the presence of benzotriazol-1-yloxytris-(dimethylamino)phosphonium hexafluorophosphate (BOP) 22) produced the 3-N-(2-naphtylacetamido)-3-chloropyridazine 4. Finally we proceeded to a palladium-catalyzed Suzuki cross-coupling reaction between acetamidopyridazine derivative 4 and a commercially available arylboronic acid. However, none of the several literature conditions 23, 24) allowed us to obtain 5b with satisfying yields (see Table 1 ).
The key difficulty in preparing compound 5b lies in the cross-coupling reaction at last step. It can be explained by a stacking effect of the naphtyl ring with the pyridazine ring hindering the catalyst approach and by the electron withdrawing effect of amide function on pyridazine ring. To overcome this difficulty, the 3-N-(2-naphtylacetamido)-6-arylpyridazines 5a-k (Table 2) were synthesized as outlined in route b of Chart 1. First a Suzuki cross-coupling reaction of available arylboronic acids with 3-amino-6-chloropyridazine 3 described previously 25) was used to prepare 3-amino-6-arylpyridazine 6 with 12-60% yields. The acetamidopyridazine derivatives 5a-k were then prepared in 18-45% yields by coupling the activated 2-naphtylacetic acid with the 3-amino-6-arylpyridazine 6 using the diimidazolylcarbodiimide (DIC) procedure described by Honma et al. 26) The derivatives 5 obtained above were evaluated for their affinity for the NPY 5 as well as the NPY 1 receptors. None of the prepared compounds exhibited significant affinity ( Table  2 ). This finding suggests that the intramolecular hydrogen bond of compound 1 stabilizes a locked conformation in which the orientation of the carbonyl function locates the oxygen atom close to the N1 nitrogen of the pyrazole ring whereas an opposite situation is preferred for compound 5b and its analogues, the CϭN and the CϭO dipoles being located in a trans antiparallel arrangement.
In summary, a 3-step synthesis of 3-N-(2-naphtylacetamido)-6-arylpyridazines has been described as analogues of the pyrazole derivative 1 but behind the dramatically poor biological results, the working hypotheses must not be confirmed.
Experimental
All experiments were carried out under an argon atmosphere. Toluene, 1,2-dimethoxyethane (DME), tetrahydrofuran (THF) were distilled from benzophenone ketyl. Tetrakis(triphenylphosphine)palladium(0), 3,6-dichloropyridazine and arylboronic acids were purchased from Lancaster Synthesis. Melting points were determined with a Mettler FP62 apparatus and are uncorrected. Organic extracts were dried over Na 2 SO 4 . Preparation of 3-Amino-6-arylpyridazines (6a-k) The 3-amino-6-arylpyridazines 6a-k necessary for the synthesis of compounds 5a-k were synthesized by using the Suzuki procedure described in our previous paper 25) where the 3-amino-6-arylpyridazines were already prepared. Aryl boronic acids were commercially available.
General Procedure for the Preparation of 3-N-(2-Naphtyl)acetamido-6-phenylpyridazine (5a-k) Diimidazolylcarbodiimide (DIC) (1.53 mmol; 248 mg; 1.05 eq) was added to a solution of 2-naphtylacetic acid (1.46 mmol; 272 mg; 1 eq.) in THF (3.52 ml) and N,N-dimethylformamide (DMF) (1.75 ml). The mixture was stirred at room temperature over 2 h and then aminopyridazine (3) (1.46 mmol; 1 eq) was added. The solution was stirred and allowed to warm to 70°C over 4 h.
The solvents were removed by evaporation under reduce pression and the residue was diluted with AcOEt. The organic layer was washed with 1 N HCl and then with 1 N NaOH and then dried over Na 2 SO 4 . After removing the solvent by evaporation, the free base was purified by flash chromatography (AcOEt-Heptane, 2.5 : 7.5).
3-N-(2-Naphtyl)acetamido-6-phenylpyridazine (5a): White needles; mp 250°C; Rf 0.15 (AcOEt 2.5/Heptane 7. Binding Assays Binding assays for both receptors NPY 1 and NPY 5 were done as described by Duhault et al. 27) In brief, for the human Y 1 receptor binding assay, using iodinated Peptide YY (NEN), incubations were performed at 30°C for 90 min with various competitors concentrations in Buffer A (Hepes/NaOH 20 mM, pH 7.4, NaCl 10 mM, KH 2 PO 4 220 mM, CaCl 2 1.26 mM, MgSO 4 0.81 mM and bovine serum albumin 0.1%) with SK-N-MC cell membranes (50 mg of protein/ml of assay) in a total volume of 500 ml. Non-specific binding was determined in the presence of 1 mM NPY. The reaction was then stopped by filtration, the filters (GF/B, Whatman, precoated in 0.3% PEI) were extensively washed with buffer A, and counted in a gamma counter (Packard). For human Y 5 receptor binding assay, the binding was carried out with iodinated peptide YY (NEN) as follows: COS cells transfected with the human Y 5 NPY receptor were lysed and the membranes prepared by differential centrifugation. These membranes contained about 2 pmol per mg of protein of this receptor. Incubations were performed in 500 ml comprising, 20 pM final of [125I]PYY in 50 ml, 400 ml of membrane suspension (0.15 mg/ml) and competitor dilutions in 50 ml, at 30°C for 2 h. The reaction was stopped by filtration through GF/C filters (Whatman).
